efaproxiral has been researched along with Glioblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carson, K; Gerber, M; Grossman, SA; Herman, T; Kleinberg, L; Lesser, G; O'Neill, A; Pearlman, J; Phillips, P | 1 |
| Engelhard, H; Gerber, M; Grossman, SA; Kleinberg, L; Lesser, G; Pearlman, J; Piantadosi, S; Ruffer, J | 1 |
2 trial(s) available for efaproxiral and Glioblastoma
| Article | Year |
|---|---|
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Topics: Adult; Aged; Aniline Compounds; Chemotherapy, Adjuvant; Confidence Intervals; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Propionates; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Supratentorial Neoplasms; Survival Analysis; Treatment Outcome; United States | 2002 |
Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aniline Compounds; Antisickling Agents; Brain Neoplasms; Glioblastoma; Hemoglobins; Humans; Middle Aged; Propionates; Radiographic Image Enhancement; Survival Analysis | 1999 |